Brookstone Capital Management Halozyme Therapeutics, Inc. Transaction History

Brookstone Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 29, 2025	BUY	$47.74 - $65.16 $48,408 - $66,072	1,014 Added 1.67%	61,601 $3.93 Million
Q3 2024 Oct 08, 2024	SELL	$51.3 - $64.42 $56,943 - $71,506	-1,110 Reduced 1.8%	60,587 $3.47 Million
Q2 2024 Jul 18, 2024	SELL	$37.81 - $52.4 $491 - $681	-13 Reduced 0.02%	61,697 $3.23 Million
Q1 2024 Apr 15, 2024	BUY	$33.68 - $41.95 $47,219 - $58,813	1,402 Added 2.32%	61,710 $2.51 Million
Q4 2023 Jan 11, 2024	SELL	$33.32 - $42.1 $932 - $1,178	-28 Reduced 0.05%	60,308 $2.23 Million

Q3 2023 Oct 20, 2023	SELL	$36.46 - $44.03 $2,880 - $3,478	-79 Reduced 0.13%	60,336 $2.3 Million
Q1 2023 Apr 18, 2023	BUY	$32.86 - $55.7 $3,450 - $5,848	105 Added 0.17%	60,415 $2.31 Million
Q3 2022 Oct 13, 2022	SELL	$38.53 - $51.78 $1,348 - $1,812	-35 Reduced 0.06%	60,310 $2.57 Million
Q2 2022 Jul 11, 2022	BUY	$37.35 - $48.3 $1,307 - $1,690	35 Added 0.06%	60,345 $3.13 Million
Q2 2021 Jul 14, 2021	BUY	$38.84 - $51.31 $2.34 Million - $3.09 Million	60,310 New	60,310 $2.71 Million

670

128M

599K

455K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

Stay updated on Brookstone Capital Management with notifications on news.